THOMAS EDGAR HUTSON
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
- Where
- LUBBOCK, TX
- NPI
- 1609819069
- Received
- $953,227 in 717 records, 2019 to 2025 ($943,858 general, $9,369 research)
- As principal investigator
- $4,754,377 of research payments to others in 1,254 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 21 | $28,158 |
| 2024 | General payment | 26 | $31,066 |
| 2023 | General payment | 139 | $119,734 |
| 2022 | General payment | 129 | $171,302 |
| 2021 | General payment | 117 | $182,022 |
| 2021 | Research payment | 1 | $812 |
| 2020 | General payment | 110 | $166,715 |
| 2020 | Research payment | 4 | $8,556 |
| 2019 | General payment | 170 | $244,858 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Exelixis Inc. | 81 | $138,163 | 2019–2025 |
| PFIZER INC. | 80 | $119,098 | 2019–2024 |
| EMD Serono, Inc. | 75 | $113,041 | 2019–2023 |
| Janssen Biotech, Inc. | 77 | $103,111 | 2019–2025 |
| Eisai Inc. | 92 | $99,790 | 2019–2025 |
| Astellas Pharma US Inc | 66 | $67,053 | 2019–2024 |
| SEAGEN INC. | 45 | $59,243 | 2019–2023 |
| Merck Sharp & Dohme LLC | 34 | $59,212 | 2019–2025 |
| AstraZeneca Pharmaceuticals LP | 47 | $57,272 | 2020–2025 |
| Aveo Pharmaceuticals, Inc. | 36 | $49,538 | 2021–2025 |
| E.R. Squibb & Sons, L.L.C. | 21 | $24,383 | 2019–2023 |
| Gilead Sciences, Inc. | 15 | $22,906 | 2021–2023 |
| Dendreon Pharmaceuticals LLC | 11 | $10,639 | 2020–2023 |
| Clovis Oncology, Inc. | 7 | $9,840 | 2020 |
| Eisai Co., Ltd. | 2 | $6,718 | 2020–2021 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $5,786 | 2021–2024 |
| GENZYME CORPORATION | 5 | $3,491 | 2020–2023 |
| F. Hoffmann-La Roche AG | 2 | $1,569 | 2020–2021 |
| PROGENICS PHARMACEUTICALS, INC. | 1 | $1,350 | 2020 |
| Janssen Scientific Affairs, LLC | 1 | $757 | 2022 |
| ABBVIE INC. | 6 | $102 | 2024–2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 2 | $66 | 2023 |
| Janssen Pharmaceuticals, Inc | 2 | $46 | 2019 |
| Myovant Sciences Inc. | 1 | $23 | 2021 |
| Pharmacyclics LLC, an AbbVie Company | 1 | $19 | 2023 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 254 | $600,387 |
| Consulting Fee | 82 | $233,687 |
| Travel and Lodging | 153 | $64,323 |
| Honoraria | 6 | $19,900 |
| Compensation for serving as faculty or as a speaker for a medical education program | 7 | $12,810 |
| Food and Beverage | 200 | $12,225 |
| Research payment | 5 | $9,369 |
| Education | 10 | $524 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | Janssen Biotech, Inc. | $100 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-11 | Aveo Pharmaceuticals, Inc. | $6,660 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2025 | |
| 2025-11-11 | Aveo Pharmaceuticals, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2025 | |
| 2025-11-04 | AstraZeneca Pharmaceuticals LP | $1,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-31 | AstraZeneca Pharmaceuticals LP | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-25 | Aveo Pharmaceuticals, Inc. | $357 | Travel and Lodging | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-10-25 | Aveo Pharmaceuticals, Inc. | $322 | Travel and Lodging | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-10-23 | AstraZeneca Pharmaceuticals LP | $48 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-17 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-10-14 | AstraZeneca Pharmaceuticals LP | $1,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-29 | AstraZeneca Pharmaceuticals LP | $3,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-17 | Aveo Pharmaceuticals, Inc. | $64 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-08-21 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2025 | |
| 2025-06-02 | Aveo Pharmaceuticals, Inc. | $370 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2025 | |
| 2025-05-30 | Eisai Inc. | $37 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-04-24 | Aveo Pharmaceuticals, Inc. | $6,660 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2025 | |
| 2025-04-21 | Merck Sharp & Dohme LLC | $4,480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-04 | Aveo Pharmaceuticals, Inc. | $588 | Travel and Lodging | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-04-04 | Aveo Pharmaceuticals, Inc. | $309 | Travel and Lodging | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-03-28 | Exelixis Inc. | $18 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-02-14 | Exelixis Inc. | $133 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2024-11-27 | Bayer Healthcare Pharmaceuticals Inc. | $571 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2024 | |
| 2024-11-22 | AstraZeneca Pharmaceuticals LP | $3,280 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-11-14 | Aveo Pharmaceuticals, Inc. | $1,850 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2024 | |
| 2024-10-09 | Aveo Pharmaceuticals, Inc. | $740 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2024 | |
| 2024-10-01 | Exelixis Inc. | $4,620 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2024 | |
| 2024-09-19 | Exelixis Inc. | $102 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2024 | |
| 2024-08-22 | Exelixis Inc. | $1,320 | Consulting Fee | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2024 | |
| 2024-06-25 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-05-31 | Aveo Pharmaceuticals, Inc. | $134 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-31 | PFIZER INC. | $44 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-05-31 | Aveo Pharmaceuticals, Inc. | $40 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2024 | |
| 2024-05-29 | Eisai Inc. | $3,925 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-05-09 | Bayer Healthcare Pharmaceuticals Inc. | $26 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2024 | |
| 2024-05-07 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-05-03 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2024 | |
| 2024-04-30 | AstraZeneca Pharmaceuticals LP | $100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2024 | |
| 2024-04-30 | Aveo Pharmaceuticals, Inc. | $40 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2024 | |
| 2024-04-16 | Aveo Pharmaceuticals, Inc. | $41 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2024 | |
| 2024-03-19 | PFIZER INC. | $17 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2024 | |
| 2024-03-08 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-01-29 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2024 | |
| 2024-01-26 | Eisai Inc. | $40 | Food and Beverage | In-kind items and services | 2024 | ||
| 2024-01-16 | Astellas Pharma US Inc | $15 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2024 | |
| 2024-01-12 | Eisai Inc. | $14,026 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2024 | |
| 2024-01-12 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2024 | |
| 2024-01-11 | AstraZeneca Pharmaceuticals LP | $28 | Food and Beverage (3 payments) | In-kind items and services | IMJUDO Biological, Oncology | 2024 | |
| 2023-12-20 | Eisai Inc. | $2,355 | Consulting Fee | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-12-18 | Merck Sharp & Dohme LLC | $2,745 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-12-18 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | 2023 | ||
| 2023-12-07 | Eisai Inc. | $498 | Travel and Lodging | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-12-07 | Eisai Inc. | $483 | Travel and Lodging | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-12-06 | Eisai Inc. | $29 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-12-05 | Exelixis Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-12-05 | Eisai Inc. | $572 | Travel and Lodging | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-12-05 | Eisai Inc. | $199 | Travel and Lodging | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-12-04 | Pharmacyclics LLC, an AbbVie Company | $19 | Food and Beverage | In-kind items and services | EPKINLY Drug, ONCOLOGY | 2023 | |
| 2023-12-03 | Eisai Inc. | $683 | Travel and Lodging | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-11-29 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-11-28 | SEAGEN INC. | $22 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-11-27 | EMD Serono, Inc. | $2,070 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-11-17 | Merck Sharp & Dohme LLC | $3,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Biological, ONCOLOGY | 2023 | |
| 2023-11-17 | EMD Serono, Inc. | $2,070 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-11-17 | SUN PHARMACEUTICAL INDUSTRIES INC. | $37 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2023 | |
| 2023-11-16 | Eisai Inc. | $24 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-11-15 | Aveo Pharmaceuticals, Inc. | $1,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2023 | |
| 2023-11-08 | Bayer Healthcare Pharmaceuticals Inc. | $23 | Food and Beverage | In-kind items and services | Xofigo Drug, Oncology | 2023 | |
| 2023-11-07 | AstraZeneca Pharmaceuticals LP | $1,712 | Consulting Fee | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2023 | |
| 2023-11-01 | AstraZeneca Pharmaceuticals LP | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2023 | |
| 2023-10-31 | Gilead Sciences, Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Trodelvy Drug, ONC | 2023 | |
| 2023-10-31 | EMD Serono, Inc. | $19 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-10-26 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-10-24 | Eisai Inc. | $16 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-10-17 | EMD Serono, Inc. | $575 | Travel and Lodging | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-10-17 | EMD Serono, Inc. | $115 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-10-17 | Astellas Pharma US Inc | $20 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2023 | |
| 2023-10-10 | Merck Sharp & Dohme LLC | $28 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-06 | SEAGEN INC. | $4,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-06 | SEAGEN INC. | $1,460 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-10-06 | SEAGEN INC. | $193 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-06 | SEAGEN INC. | $193 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-06 | SEAGEN INC. | $165 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-06 | SEAGEN INC. | $165 | Travel and Lodging | In-kind items and services | 2023 | ||
| 2023-10-06 | Merck Sharp & Dohme LLC | $150 | Travel and Lodging | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-05 | Merck Sharp & Dohme LLC | $584 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-05 | Merck Sharp & Dohme LLC | $437 | Travel and Lodging | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-05 | Merck Sharp & Dohme LLC | $124 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-10-04 | EMD Serono, Inc. | $1,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-10-03 | SEAGEN INC. | $23 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-09-27 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-09-26 | Janssen Biotech, Inc. | $29 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-09-26 | Astellas Pharma US Inc | $4 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2023 | |
| 2023-09-25 | Aveo Pharmaceuticals, Inc. | $1,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2023 | |
| 2023-09-20 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-09-19 | Merck Sharp & Dohme LLC | $29 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-09-08 | AstraZeneca Pharmaceuticals LP | $20 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2023 | |
| 2023-08-30 | EMD Serono, Inc. | $1,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-08-28 | Eisai Inc. | $22 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-08-22 | Astellas Pharma US Inc | $19 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2023 | |
| 2023-08-16 | Gilead Sciences, Inc. | $5,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Trodelvy Drug, ONC | 2023 | |
| 2023-08-10 | Gilead Sciences, Inc. | $537 | Travel and Lodging | In-kind items and services | Trodelvy Drug, ONC | 2023 | |
| 2023-08-10 | Gilead Sciences, Inc. | $232 | Travel and Lodging | In-kind items and services | Trodelvy Drug, ONC | 2023 | |
| 2023-08-10 | Gilead Sciences, Inc. | $114 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2023 | |
| 2023-08-10 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-08-08 | Dendreon Pharmaceuticals LLC | $14 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-07-27 | GENZYME CORPORATION | $88 | Food and Beverage | In-kind items and services | JEVTANA Drug, Oncology | 2023 | |
| 2023-07-27 | GENZYME CORPORATION | $23 | Food and Beverage | In-kind items and services | JEVTANA Drug, Oncology | 2023 | |
| 2023-07-26 | Exelixis Inc. | $3,300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-07-26 | Exelixis Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-07-26 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-07-25 | Aveo Pharmaceuticals, Inc. | $1,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2023 | |
| 2023-07-21 | AstraZeneca Pharmaceuticals LP | $2,750 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2023 | |
| 2023-07-19 | Eisai Inc. | $24 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-07-15 | Exelixis Inc. | $218 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Oncology | 2023 | |
| 2023-07-15 | Exelixis Inc. | $218 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Oncology | 2023 | |
| 2023-07-13 | E.R. Squibb & Sons, L.L.C. | $18 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-07-13 | Astellas Pharma US Inc | $7 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2023 | |
| 2023-07-11 | AstraZeneca Pharmaceuticals LP | $455 | Travel and Lodging | In-kind items and services | LYNPARZA Drug, Oncology | 2023 | |
| 2023-07-11 | AstraZeneca Pharmaceuticals LP | $108 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2023 | |
| 2023-06-29 | Janssen Biotech, Inc. | $84 | Education | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-06-22 | Merck Sharp & Dohme LLC | $23 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-06-20 | SEAGEN INC. | $25 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-06-05 | Eisai Inc. | $35 | Food and Beverage | Cash or cash equivalent | 2023 | ||
| 2023-05-30 | Exelixis Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-05-30 | AstraZeneca Pharmaceuticals LP | $21 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2023 | |
| 2023-05-25 | EMD Serono, Inc. | $3,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-05-25 | EMD Serono, Inc. | $1,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-05-24 | Aveo Pharmaceuticals, Inc. | $1,400 | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | FOTIVDA Drug, Oncology | 2023 | |
| 2023-05-23 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-05-18 | Eisai Inc. | $1,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-05-18 | Eisai Inc. | $115 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-05-18 | Merck Sharp & Dohme LLC | $22 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-05-16 | SEAGEN INC. | $21 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-05-16 | SEAGEN INC. | $3 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-05-09 | EMD Serono, Inc. | $3,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-05-08 | SEAGEN INC. | $3,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, Oncology | 2023 | |
| 2023-05-08 | SEAGEN INC. | $543 | Travel and Lodging | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-05-08 | SEAGEN INC. | $130 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-05-04 | PFIZER INC. | $15 | Food and Beverage | In-kind items and services | INLYTA Drug, ONCOLOGY | 2023 | |
| 2023-05-03 | Eisai Inc. | $1,360 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-05-02 | Astellas Pharma US Inc | $730 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Padcev Drug, Oncology | 2023 | |
| 2023-05-02 | Eisai Inc. | $23 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-04-28 | Exelixis Inc. | $412 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-04-26 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-04-25 | SEAGEN INC. | $3,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, Oncology | 2023 | |
| 2023-04-25 | SEAGEN INC. | $430 | Travel and Lodging | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-04-24 | Dendreon Pharmaceuticals LLC | $2,490 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-04-24 | Dendreon Pharmaceuticals LLC | $433 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-04-21 | PFIZER INC. | $2,190 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | 2023 | |
| 2023-04-21 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-04-18 | EMD Serono, Inc. | $345 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-04-18 | EMD Serono, Inc. | $124 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-04-18 | EMD Serono, Inc. | $45 | Travel and Lodging | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-04-18 | E.R. Squibb & Sons, L.L.C. | $29 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2023 | |
| 2023-04-13 | Astellas Pharma US Inc | $3 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2023 | |
| 2023-04-07 | Astellas Pharma US Inc | $85 | Education | In-kind items and services | 2023 | ||
| 2023-04-06 | Astellas Pharma US Inc | $85 | Education | In-kind items and services | 2023 | ||
| 2023-04-06 | Astellas Pharma US Inc | $85 | Education | In-kind items and services | 2023 | ||
| 2023-04-04 | Exelixis Inc. | $1,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-04-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | $28 | Food and Beverage | In-kind items and services | YONSA Drug, Oncology | 2023 | |
| 2023-03-30 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-03-28 | SEAGEN INC. | $23 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2023 | |
| 2023-03-22 | Merck Sharp & Dohme LLC | $7,320 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2023 | ||
| 2023-02-22 | GENZYME CORPORATION | $3,245 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | JEVTANA Drug, Oncology | 2023 | |
| 2023-02-21 | Aveo Pharmaceuticals, Inc. | $144 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2023 | |
| 2023-02-21 | Bayer Healthcare Pharmaceuticals Inc. | $25 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2023 | |
| 2023-02-20 | Janssen Biotech, Inc. | $4,390 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2023 | |
| 2023-02-20 | Janssen Biotech, Inc. | $439 | Travel and Lodging | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-02-20 | Janssen Biotech, Inc. | $86 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-02-20 | Janssen Biotech, Inc. | $27 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2023 | |
| 2023-02-13 | Dendreon Pharmaceuticals LLC | $2,490 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-02-13 | Dendreon Pharmaceuticals LLC | $540 | Travel and Lodging | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-02-09 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | XTANDI Drug, ONCOLOGY | 2023 | |
| 2023-02-07 | Dendreon Pharmaceuticals LLC | $1,245 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2023-02-07 | Astellas Pharma US Inc | $22 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2023 | |
| 2023-02-06 | AstraZeneca Pharmaceuticals LP | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2023 | |
| 2023-01-30 | Janssen Biotech, Inc. | $675 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2023 | |
| 2023-01-26 | EMD Serono, Inc. | $367 | Travel and Lodging | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-01-26 | EMD Serono, Inc. | $97 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-01-24 | Bayer Healthcare Pharmaceuticals Inc. | $1,142 | Consulting Fee | Cash or cash equivalent | Xofigo Drug, Oncology | 2023 | |
| 2023-01-24 | Merck Sharp & Dohme LLC | $15 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-01-18 | EMD Serono, Inc. | $20 | Food and Beverage | Cash or cash equivalent | BAVENCIO Drug, Oncology | 2023 | |
| 2023-01-16 | Eisai Inc. | $17 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-01-13 | E.R. Squibb & Sons, L.L.C. | $1,200 | Consulting Fee | Cash or cash equivalent | 2023 | ||
| 2023-01-10 | Merck Sharp & Dohme LLC | $19 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2023 | |
| 2023-01-06 | Dendreon Pharmaceuticals LLC | $830 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2023 | |
| 2022-12-31 | Astellas Pharma US Inc | $730 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Drug, Oncology | 2022 | |
| 2022-12-31 | EMD Serono, Inc. | $715 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2022 | ||
| 2022-12-31 | EMD Serono, Inc. | $234 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | 2022 | ||
| 2022-12-20 | SEAGEN INC. | $21 | Food and Beverage | In-kind items and services | PADCEV Biological, Oncology | 2022 | |
| 2022-12-15 | E.R. Squibb & Sons, L.L.C. | $19 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2022 | |
| 2022-12-14 | Astellas Pharma US Inc | $3,650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Xtandi Drug, Oncology | 2022 | |
| 2022-12-14 | Astellas Pharma US Inc | $398 | Travel and Lodging | Cash or cash equivalent | Xtandi Drug, Oncology | 2022 | |
| 2022-12-13 | Janssen Biotech, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ERLEADA Drug, Oncology | 2022 | |
| 2022-12-08 | SEAGEN INC. | $2,190 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, Oncology | 2022 | |
| 2022-12-07 | Astellas Pharma US Inc | $15 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2022 | |
| 2022-12-06 | Gilead Sciences, Inc. | $5 | Food and Beverage | In-kind items and services | Trodelvy Drug, ONC | 2022 | |
| 2022-11-29 | EMD Serono, Inc. | $1,380 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bavencio Drug, Oncology | 2022 | |
| 2022-11-17 | Merck Sharp & Dohme LLC | $22 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2022 | |
| 2022-11-16 | Merck Sharp & Dohme LLC | $4,270 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2022 |
The latest 200 records of 717.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-08-22 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $1,100 | Phase I/II Pharmacokinetic Multi-Tumor Study of Subcutaneous Formulation of Nivolumab Monotherapy | 2025 |
| 2025-03-26 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,411 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-03-26 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,125 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-03-26 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,411 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-03-26 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,411 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-02-28 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,125 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-01-17 | AstraZeneca UK Limited | THE US ONCOLOGY NETWORK | $10,478 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination | 2025 |
| 2025-01-15 | Novartis Pharmaceuticals Corporation | TEXAS ONCOLOGY BAYLOR CAS CENTER | $5,404 | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Rece | 2025 |
| 2024-12-13 | Janssen Research & Development, LLC | US ONCOLOGY RESEARCH INC | $9,500 | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Depriva | 2024 |
| 2024-10-17 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $6,841 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2024 |
| 2024-08-29 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $8,000 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2024 |
| 2024-08-28 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $1,250 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2024 |
| 2024-08-14 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,125 | BLU667 1101 ARROW ongoing | 2024 |
| 2024-07-24 | Exelixis Inc. | Texas Oncology, P.A. | $3,011 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-07-12 | Exelixis Inc. | Texas Oncology, P.A. | $13,200 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-07-01 | Exelixis Inc. | Texas Oncology, P.A. | $500 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-06-26 | Merck Sharp & Dohme LLC | Baylor University Medical Center | $283,680 | A PHASE 1B,2, OPEN-LABEL, SAFETY, TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVA | 2024 |
| 2024-06-05 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $1,250 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2024 |
| 2024-06-05 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,768 | BLU667 1101 ARROW ongoing | 2024 |
| 2024-05-31 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $235 | BLU667 1101 ARROW ongoing | 2024 |
| 2024-05-28 | Novartis Pharmaceuticals Corporation | TEXAS ONCOLOGY BAYLOR CAS CENTER | $186 | An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus O | 2024 |
| 2024-04-25 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $117 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2024 |
| 2024-04-15 | Genentech, Inc. | Texas Oncology PA | $625 | Tecentriq Oncology Extension Study | 2024 |
| 2024-04-15 | Genentech, Inc. | Texas Oncology PA | $11 | Tecentriq Oncology Extension Study | 2024 |
| 2024-04-15 | Genentech, Inc. | Texas Oncology PA | $68 | Tecentriq Oncology Extension Study | 2024 |
| 2024-04-15 | Genentech, Inc. | Texas Oncology PA | $200 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-27 | Exelixis Inc. | Texas Oncology, P.A. | $1,500 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-03-27 | Exelixis Inc. | Texas Oncology, P.A. | $1,000 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-03-27 | Exelixis Inc. | Texas Oncology, P.A. | $500 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $1,020 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $68 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $753 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $1,020 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $11 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $753 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $200 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-15 | Genentech, Inc. | Texas Oncology PA | $1,020 | Tecentriq Oncology Extension Study | 2024 |
| 2024-03-11 | Exelixis Inc. | Texas Oncology, P.A. | $2,000 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-03-11 | Exelixis Inc. | Texas Oncology, P.A. | $2,000 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-03-11 | Exelixis Inc. | Texas Oncology, P.A. | $750 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-03-11 | Exelixis Inc. | Texas Oncology, P.A. | $10,000 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-03-11 | Exelixis Inc. | Texas Oncology, P.A. | $1,000 | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clea | 2024 |
| 2024-03-04 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $3,300 | Phase I/II PK Multi Tumor SubQ Formulation Nivo Mono | 2024 |
| 2024-03-01 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,267 | BLU667 1101 ARROW ongoing | 2024 |
| 2024-02-28 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $3,750 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2024 |
| 2024-02-20 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $600 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2024 |
| 2024-02-20 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $3,317 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $11 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $753 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $200 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $68 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $200 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $68 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-15 | Genentech, Inc. | Texas Oncology PA | $11 | Tecentriq Oncology Extension Study | 2024 |
| 2024-02-14 | EMD Serono, Inc. | Texas Oncology, P.A. | $140 | PATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-2020 | 2024 |
| 2024-02-09 | Exelixis Inc. | Texas Oncology, P.A. | $500 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-02-09 | Exelixis Inc. | Texas Oncology, P.A. | $2,800 | A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subje | 2024 |
| 2024-01-31 | Novartis Pharmaceuticals Corporation | TEXAS ONCOLOGY BAYLOR CAS CENTER | $850 | PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Rece | 2024 |
| 2024-01-29 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $272 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2024 |
| 2024-01-25 | Amgen Inc. | TEXAS ONCOLOGY - DALLAS FORT WORTH | $1,022 | BEMA Ph2 Basket Study | 2024 |
| 2024-01-22 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $16,642 | Phase III 1L Metastatic RCC Nivo/Ipi/Cabo | 2024 |
| 2024-01-15 | E.R. Squibb & Sons, L.L.C. | Texas Onco Southwest Fort Worth | $3,740 | Phase I/II PK Multi Tumor SubQ Formulation Nivo Mono | 2024 |
| 2024-01-15 | AstraZeneca Pharmaceuticals LP | TEXAS ONCOLOGY SOUTHWEST FORT WORTH | $27,396 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination | 2024 |
| 2024-01-15 | Genentech, Inc. | Texas Oncology PA | $68 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-15 | Genentech, Inc. | Texas Oncology PA | $753 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-15 | Genentech, Inc. | Texas Oncology PA | $200 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-15 | Genentech, Inc. | Texas Oncology PA | $625 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-15 | Genentech, Inc. | Texas Oncology PA | $11 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-15 | E.R. Squibb & Sons, L.L.C. | Texas Onco Southwest Fort Worth | $10,040 | Phase III 1L Metastatic RCC Nivo/Ipi/Cabo | 2024 |
| 2024-01-15 | Amgen Inc. | TEXAS ONCOLOGY - DALLAS FORT WORTH | $2,550 | BEMA Ph2 Basket Study | 2024 |
| 2024-01-12 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $2,336 | Tecentriq Oncology Extension Study | 2024 |
| 2024-01-10 | AstraZeneca UK Limited | THE US ONCOLOGY NETWORK | $74,305 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination | 2024 |
| 2024-01-04 | E.R. Squibb & Sons, L.L.C. | Texas Virtual Care | $3,800 | Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma | 2024 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Baylor Sammons Cancer Center, Texas Oncology | $1,934 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2023 |
| 2023-12-31 | Merck Sharp & Dohme LLC | Baylor Sammons Cancer Center, Texas Oncology | $10,002 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Ad | 2023 |
| 2023-10-31 | EMD Serono, Inc. | Texas Oncology, P.A. | $2,500 | PATRIOT II US Prospective 1st Line Maintenance of Avelumab in UC-2020 | 2023 |
| 2023-10-26 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $117 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2023 |
| 2023-10-17 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $1,940 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2023 |
| 2023-10-17 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $1,940 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2023 |
| 2023-10-17 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $1,440 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2023 |
| 2023-10-10 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $3,504 | Tecentriq Oncology Extension Study | 2023 |
| 2023-10-05 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $8,903 | Tecentriq Oncology Extension Study | 2023 |
| 2023-10-05 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $1,250 | Tecentriq Oncology Extension Study | 2023 |
| 2023-10-02 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $1,287 | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2023 |
| 2023-09-26 | Exelixis Inc. | US ONCOLOGY RESEARCH LLC | $9,000 | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in | 2023 |
| 2023-09-15 | E.R. Squibb & Sons, L.L.C. | Northwest Cancer Specialists, Pc | $255 | Phase III 1L Metastatic RCC Nivo/Ipi/Cabo | 2023 |
| 2023-08-25 | Exelixis Inc. | Texas Oncology, P.A. | $159 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2023 |
| 2023-08-15 | PFIZER INC. | US ONCOLOGY RESEARCH LLC | $702 | A PHASE 3 MULTINATIONAL RANDOMIZED OPENLABEL PARALLELARM STUDY OF AVELUMAB MSB0010718C IN COMBINATION WITH AXITINIB INLY | 2023 |
| 2023-08-15 | AstraZeneca Pharmaceuticals LP | TEXAS ONCOLOGY SOUTHWEST FORT WORTH | $7,650 | A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination | 2023 |
| 2023-07-12 | Exelixis Inc. | Texas Oncology, P.A. | $500 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2023 |
| 2023-07-12 | Exelixis Inc. | Texas Oncology, P.A. | $1,200 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2023 |
| 2023-07-12 | Exelixis Inc. | Texas Oncology, P.A. | $150 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2023 |
| 2023-07-10 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $4,672 | Tecentriq Oncology Extension Study | 2023 |
| 2023-07-07 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $236 | A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Sub | 2023 |
| 2023-07-07 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $5,648 | A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Sub | 2023 |
| 2023-07-07 | Aveo Pharmaceuticals, Inc. | US ONCOLOGY RESEARCH LLC | $436 | A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Sub | 2023 |
| 2023-07-07 | Eisai Inc. | TEXAS ONCOLOGY, PA | $155 | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit | 2023 |
| 2023-07-05 | Genentech, Inc. | UNITED STATES ONCOLOGY RESEARCH LLC | $2,698 | Tecentriq Oncology Extension Study | 2023 |
| 2023-06-27 | E.R. Squibb & Sons, L.L.C. | Texas Oncology-Baylor Charles A Sammons Cancer Center | $180 | Phase I/II PK Multi Tumor SubQ Formulation Nivo Mono | 2023 |
| 2023-06-26 | Exelixis Inc. | Texas Oncology, P.A. | $575 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2023 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Lubbock, TX, county Lubbock County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Lubbock, TX | County Lubbock County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 264,814 | 318,884 | 30,188,424 |
| Population, 2020 census P1 | 257,141 | 310,639 | 29,145,505 |
| Median age B01002 | 30.5 | 31.9 | 35.6 |
| Under 18 B01001 | 22.9% | 23.5% | 25.0% |
| 65 and over B01001 | 12.8% | 13.3% | 13.4% |
| Households B11001 | 107,086 | 126,225 | 10,992,816 |
| Foreign born B05002 | 6.3% | 6.1% | 17.6% |
| Median household income B19013 | $60,895 | $64,155 | $78,476 |
| Median family income B19113 | $82,149 | $83,971 | $94,599 |
| Per capita income B19301 | $35,237 | $35,808 | $40,752 |
| Poverty rate B17001 | 18.9% | 17.1% | 13.8% |
| Unemployment rate B23025 | 5.2% | 4.9% | 5.3% |
| Civilian labor force B23025 | 140,300 | 166,217 | 15,233,563 |
| Mean commute (minutes) B08013 | 16.3 | 17.1 | 26.7 |
| Bachelor's degree or higher B15003 | 35.1% | 33.4% | 33.8% |
| Housing units B25001 | 118,143 | 139,344 | 12,128,515 |
| Owner-occupied B25003 | 51.2% | 55.5% | 62.6% |
| Renters B25003 | 48.8% | 44.5% | 37.4% |
| Median home value B25077 | $212,400 | $214,100 | $283,800 |
| Median gross rent B25064 | $1,182 | $1,178 | $1,403 |
| White, not Hispanic B03002 | 49.6% | 51.5% | 39.1% |
| Black B03002 | 7.7% | 6.7% | 11.9% |
| Hispanic or Latino B03002 | 36.6% | 36.2% | 39.7% |
| Asian B03002 | 2.7% | 2.4% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Lubbock, TX.
Comments